-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 WwKicNtwkOvnzIXMFvdYFdQKyVchFlWTxJiI1s6KUpbv9uTAnD4N8oC3gxyqx+k+
 zl1kUVxA5RKM/P88uLKsrw==

<SEC-DOCUMENT>0000930413-09-000064.txt : 20090106
<SEC-HEADER>0000930413-09-000064.hdr.sgml : 20090106
<ACCEPTANCE-DATETIME>20090106150800
ACCESSION NUMBER:		0000930413-09-000064
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20090102
FILED AS OF DATE:		20090106
DATE AS OF CHANGE:		20090106

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Renfro Phillip M
		CENTRAL INDEX KEY:			0001313575

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-12957
		FILM NUMBER:		09509688

	BUSINESS ADDRESS:	
		BUSINESS PHONE:		908-541-8650

	MAIL ADDRESS:	
		STREET 1:		C/O ENZON PHARM.,685 RTE 202/206
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ENZON PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000727510
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				222372868
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		685 ROUTE 202/206
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807
		BUSINESS PHONE:		908 541 8671

	MAIL ADDRESS:	
		STREET 1:		685 ROUTE 202/206
		STREET 2:		ATT:  GENERAL COUNSEL
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ENZON PHARMACEUTICALS  INC
		DATE OF NAME CHANGE:	20021211

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ENZON PHARMACEUTICAL  INC
		DATE OF NAME CHANGE:	20021210

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ENZON INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>c56235_ex.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0303</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2009-01-02</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0000727510</issuerCik>
        <issuerName>ENZON PHARMACEUTICALS INC</issuerName>
        <issuerTradingSymbol>ENZN</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001313575</rptOwnerCik>
            <rptOwnerName>Renfro Phillip M</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O ENZON PHARMACEUTICALS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>685 RTE 202/206</rptOwnerStreet2>
            <rptOwnerCity>BRIDGEWATER</rptOwnerCity>
            <rptOwnerState>NJ</rptOwnerState>
            <rptOwnerZipCode>08807</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
                <footnoteId id="F1"/>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>5.80</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2009-01-02</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>33453</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <value>2010-01-02</value>
            </exerciseDate>
            <expirationDate>
                <value>2019-01-02</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>33453</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>33453</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Annual options granted to non-employee directors of Issuer pursuant to Issuer's 2001 Incentive Stock Plan and qualified under
 Rule 16b-3(d). The options will be fully vested and exercisable in one (1) tranche one (1) year after the date of the grant
 if the reporting person remains on the Board until such date.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>Craig A. Tooman, Attorney-In-Fact</signatureName>
        <signatureDate>2009-01-06</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----